Don’t Miss This Bullish Run on OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) shares rose 36.57% on Friday to $0.915 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.95. The company has a market cap of $128.82 million at 135.31 million shares outstanding.
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. As such, it is engaged in the research and development of cannabis-based medical products for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications.
The company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. It was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device, and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder migraines and a delivery system.
Last week, OWC Pharmaceutical Corp announced that it would be presenting at the Wall Street Conference, which will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach, Boca Raton, Florida, on Wednesday, March 1, 2017. This premiere conference in the venture capital arena and small-cap marketplace includes industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, who attend to discuss significant trends in the financial markets.
The Wall Street Conference is one of the leading conferences for small-cap investors and OWC is excited to be a part of it. OWC continues to make significant progress in the research and development of cannabis-centric medical treatments, specifically with our psoriasis cream, which is being readied for the U.S. and European markets. We are focused on having our products on the shelves in the MMJ states this year. I am very much looking forward to discussing the Company with conference attendees,” remarked Ziv Turner, OWC Pharmaceutical Corp’s VP Business development and Managing Director of One World Cannabis.
Member of the company’s Advisory Board, Jeffrey Friedland, is a featured speaker at the Conference and is expected to discuss the opportunities for public company investments in the cannabis sector, and the positive impact that Israeli science and companies are having on the U.S. and Canadian cannabis markets. He is also CEO of Intiva Inc., which was an early-stage investor in OWC, and the author of Marijuana: The World‘s Most Misunderstood Plant.
The legal cannabis market has expanded considerably over the past two years, generating significant and growing investor interest. However, there are only a handful of publicly-traded companies focused on cannabinoid-based, pharmaceutical development and a true scientific approach to product development. I intend to discuss what I see as the publicly-traded cannabis opportunities at the Conference,” Friedland noted.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
How Canopy Growth Corp (TSE:WEED) Shares Reacted to Earnings
Canopy Growth Corp (TSE:WEED) shares were down 8.08% to $11.95 on Tuesday and flat in after-hours trading. Share prices have been trading in a 52-week range of $2.70 to $17.86. The company has a market cap of $1.99 billion at 159.13 million shares outstanding.
Formerly known as Tweed Marijuana Inc, Canopy Growth Corp is a diversified cannabis company. Through its subsidiaries Tweed Inc. (Tweed), Bedrocan Canada Inc. (Bedrocan) and Tweed Farms Inc. (Tweed Farms), is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan.
Tweed is a licensed producer of medical marijuana. Tweed’s commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year. Tweed’s built-out production capacity is over 10 climate controlled indoor growing rooms. Bedrocan is a medical-grade cannabis. Bedrocan’s over 52,000 square feet production facility in Toronto, Ontario is licensed, and includes over 30 vegetative and growing rooms, and over three dispensing rooms.
Canopy Growth Corp recently printed its quarterly earnings figures and investors seem unimpressed. The company reported over 29,000 registered patients at December 31, 2016 compared to over 8,000 at December 31, 2015, representing a greater than 260% increase. It made revenue of $9.8 million, which amounts to a 15% increase over the second quarter in the fiscal year 2017 and 180% increase over the prior year period.
However, the company admitted that revenue growth was limited by the product mix available for sale, as supply was limited in the quarter due to rigorous procedures to fully test the record harvest and approve the extensive product released for sale subsequent to quarter end. Still, it was able to harvest a record 5,264 kilograms compared to 1,711 kilograms in the second quarter fiscal year 2017, which amounts to a 208% increase.
The third quarter provided new opportunities and challenges for our business, with demand largely exceeding supply throughout the quarter,” said Bruce Linton, Chairman & CEO of Canopy Growth Corp. “A function of our growing patient base, the time required to move from a record harvest to sale, and an extensive phenotyping exercise to establish breeding stock and further elevate our product offering all resulted in constrained product available for sale during the quarter. The successful late-quarter harvest of the Tweed Farms facility running at full capacity has begun to ease supply constraints while at the same time we have introduced a new diversity of product into our online store under the Tweed, Leafs By Snoop and DNA Genetics banners, driving strong sales this month.”
Other developments over the period included the acquisition of a 472,000 square foot and 42 acre property at 1 Hershey Drive, Smiths Falls, Ontario on January 13, 2017. This is on top of the acquisition of Mettrum Health Corp on January 31, 2017 and the change in the TSX trading symbol from CGC to WEED early this month.
We continued to push the boundaries of our business during the quarter through multiple strategic accomplishments that will help drive our future growth. We worked to strengthen our market position in Canada with our move to acquire Mettrum and the acquisition of Vert Cannabis to establish a unique brand presence in Quebec. We also established a base of operations in Germany, a strategic future market for Canopy, with the purchase of cannabis distributor, MedCann GMBH,” added Linton.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Why Sycamore Entertainment Group Inc (OTCMKTS:SEGI) Shares Slumped
Sycamore Entertainment Group Inc (OTCMKTS:SEGI) shares dropped 42.86% to $0.00040 and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.00. The company has a market cap of $971K at 1.39 billion shares outstanding.
Sycamore Entertainment Group Inc is an independent film marketing and distribution company that specializes in the acquisition, distribution and development of marketing campaigns. It focuses on participating in various other streams related to filmed entertainment content distribution, as well as various other activities related to funding the print and advertising of acquired feature films. Its film marketing and distribution operations include film acquisitions, publicity, print advertising, billboard advertising, film distribution and online marketing.
The company also offers services, including acquiring films; publicity and public relations, and online content writing and search engine optimization services. It provides distribution services for release commercial films. It represents independent film companies that create domestic and foreign feature films. Its operations include Film Library Development, Distribution, Print and Advertising Fund, and Production.
Just last week, Sycamore Entertainment Group announced that it has executed a “film rights purchase agreement” with top Hollywood producers.
We are excited to be working some of the best talents in Hollywood,” says Edward Sylvan, CEO of Sycamore Entertainment Group. “Our arrangement with LDJ Capital called for us to bring ‘best in class’ projects to the table, I feel we are accomplishing these objectives. We are looking forward to the time when we are able discuss the project in more detail. With the working capital in hand we are in the best position to increase shareholder value by spending on corporate marketing and executing on our lineup of film and TV projects.”
This contributed to more than 70% gains in Sycamore Entertainment Group shares at the start of the week but more than half of this was given back when it announced a self-imposed share issuance lockout.
The lack of trust in OTC issuers by Penny Stock traders has been a major roadblock to issuers when trying to raise the necessary working capital needed to grow their business. Sycamore is taking a first step in restoring that trust with its shareholders,” the company statement indicated. “Effective immediately, we will apply a self-imposed share structure lockout for a minimum of 60 days. During that time, there will be no issuances of new shares, nor will there be any increase to the authorized share capital. It is my opinion, that the current issued and outstanding is ideal to encourage liquidity and allows investors of all sizes to participate in our market.”
In effect, Sycamore Entertainment Group will not be engaging in any reverse split at any time whatsoever in order to provide traders and investors with the confidence that they can participate in the market and not have the share value be eroded due to unnecessary dilution.
We would like to send a message loud and clear that we support the trading and investing community and that we share common goals. The sooner that we can align our interests the faster we can move the company ahead. The new laws allow us to take the power away from dilutive financing options and places it back into the hands of the traders and shareholders who continue to support what we do,” it concluded.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Why Pharmacyte Biotech Inc (OTCMKTS:PMCB) Shares Fell 13%
Pharmacyte Biotech Inc (OTCMKTS:PMCB) shares were down 13.04% on Wednesday but recovered 1.39% in after-hours trading. Share prices have been trading in a 52-week range of $0.02 to $0.17. The company has a market cap of $96.95 million at 849.90 million shares outstanding.
Pharmacyte Biotech Inc is a clinical-stage biotechnology company that is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This Cell-in-a-Box technology will be used as a platform upon which treatments for various types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed.
Aside from that, Pharmacyte Biotech is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type I diabetes and insulin-dependent Type II diabetes based upon the encapsulation of a human cell line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body using its Cell-in-a-Box technology.
Pharmacyte Biotech recently announced that an audio recording of the company’s shareholder call, which was held on February 7 is now available for playback.
I would like to thank everyone who listened to our shareholder call update yesterday. I would also like to apologize for the call abruptly cutting off during the question and answer session. The call stopped at the one-hour mark. That has never happened before. The call was scheduled to continue for one and a half hours. Since we wanted to answer all of the questions that were submitted, we have recorded the balance of the questions and answers,” explained Pharmacyte Biotech CEO Kenneth Waggoner.
The audio recording with remaining questions and answers of the shareholder call can be found here: https://fccdl.in/b0lcv21IV.
Earlier in the year, Pharmacyte Biotech announced its plans to initiate a clinical trial in pancreatic cancer, involving the application of Cell-in-a-Box to go head to head with the current gold standard in pancreatic cancer treatment called gemcitabine. The company has completed a pre-IND meeting with the FDA so it could proceed with the Phase 1 of treatment soon. Once this announcement is made, further bullish upside is expected for the company. This month, the company was granted orphan drug designation for pancreatic cancer treatment.
Pharmacyte Biotech has made a huge upside breakout from its slow downtrend for the most part of 2016, signaling further upside for the stock. Volume has been subdued since the bullish break, leading to some profit-taking and consolidation, but the bullish flag remains intact even as price has pulled back. Buyers could simply be waiting for more updates from the company before taking the stock further north, possibly for another test of the $0.15 mark in the near-term then onto $0.20 and beyond.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
One Bullish Prospect After Another for Zerez Holdings Inc (OTCMKTS:ZRZH)
Zerez Holdings Inc (OTCMKTS:ZRZH) shares were up 18.18% on Tuesday to $0.0449 and flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.06. The company has a market cap of $211 million at 5.57 billion shares outstanding.
Zerez Holdings Inc is a public equity corporation that is focused on the advanced agriculture and cannabis industries with plans to grow through acquisition, strategic alliances, and proprietary intellectual property. The company’s wholly owned subsidiary Next Generation Farming provides turnkey commercial greenhouse and automation systems that improve yields and decrease water consumption for cultivators of organic food and cannabis crops.
In a press release yesterday, Zerez Holdings Inc reported that its subsidiary Next Generation Farming Inc has signed its Co-Marketing partner Sweet Leaf Hydroponics to a wholesale purchase contract for a minimum of $1 million dollars worth of NextGen’s “SMART by Design” line of advanced and automated greenhouse systems by the end of the year. On top of this, Sweet Leaf has also ordered 2 30ft. x 24ft. production models to be built as walk-thru demonstration facilities at each of their sales locations.
“It was imperative that we enlisted the feedback about our marketing strategy, product designs, configurations, pricing and overall sales and support strategy with Jay and our extended team at Sweet Leaf Hydro. They sell millions in revenue to thousands of clients and we wanted to leave no stone unturned before our upcoming launch. Obviously we have a good plan for Jay to make such a strong minimum sales commitment to us,” said John Taylor and Don Smith of Zerez Holdings Inc.
For Jay DeSalvatore, president of Sweet Leaf Hydroponics, the companies are in full alignment and are confident that they can easily re-sell a million dollars of their products by the end of the year. Sweet Leaf has hundreds of regular customers and lots of immediate greenhouse sales opportunities.
“The data we continue to see is that the smart greenhouse marketplace is worth a minimum of $6 billion in 2017. Although we see most of our sales being on the commercial scale, with multi-faceted customer relationships, we have created some unique and surprising products that will be available for immediate purchase when we launch. We intend to smartly capture our profitable share of this market. If Zerez Holdings and Next Generation Farming earn just 10-20% market share, that translates into potential revenues of $600 Million to $1.2 billion annually. Obviously, we are ramping our business quickly, and we are confident we can handle that level of growth when it comes,” Taylor added.
In January, Zerez Holdings Inc announced that it has sold another “SMART by Design” greenhouse system to its first repeat client, a Northern California Cannabis cultivation company, from earlier in the month.
“When a client comes back and orders from you again that is our definition of consumer confidence. We are very pleased that the trust, confidence and great working relationship with our customer has resulted in a second order in less than 10 days,” Taylor shared.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Why Earth Science Tech Inc (OTCMKTS:ETST) Shares Rose Nearly 30%
Earth Science Tech Inc (OTCMKTS:ETST) shares were up 27.78% to $1.38 on Monday to $1.38 and flat in after-hours trading. Share prices have been trading in a 52-week range of $0.18 to $1.70. The company has a market cap of $55.85 million at 40.47 million shares outstanding.
Earth Science Tech Inc is a biotechnology company that is focused on nutraceuticals and bioceuticals for use in various industries, such as health, wellness, nutritional supplements, cosmetic and alternative medicine to manage illnesses and the quality of life for consumers around the world. It sells its products through its retail store located in Coral Gables, Florida, and through the Internet.
The company is also focused on delivering nutritional and dietary supplements that help with treating symptoms, such as chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea and aging. This may include products, such as vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products. These products will be in various formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs.
In a press release this week, Earth Science Tech Inc announced that itsnew wholly owned subsidiary, Cannabis Therapeutics, Inc. will be releasing new Cannabinoid-based Drugs and Nutraceuticals. In particular, Cannabis Therapeutics will begin by inventing & launching 2 new cannabinoid-based pharmaceutical drugs and 3 new advanced cannabinoid-based nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, invention, technology and future technology.
“I am very enthusiastic about Cannabis Therapeutics position in the cannabis industry to become a leader in cannabinoid research and development. Our imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). We look to announce later this week a New Scientific Advisory Board which will include myself, Dr. Michel Aube, as the Chairman of the Advisory board to Cannabis Therapeutics, Inc. as well as other World Class Scientists,” said Dr. Michael Aube, CEO of Earth Science Tech Inc.
Cannabis Therapeutics plans on distinguishing itself from many competing cannabinoid-focused biotechnology companies with its competent capital apportionment. Its board of directors and upcoming new scientific advisory board intends to broaden the current operations of the Cannabis Therapeutics to include a variety of other products, solutions, laboratories and expertise. Its goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products.
ETST is extremely fortunate to have attracted world leaders to our executive leadership team and Board of Advisors. All of them are contributing their passion, time and expertise to the development of Cannabis Therapeutics unique cannabinoid-based products and solutions. Cannabis Therapeutics goal is to help advance the cannabis-cannabinoid healthcare industry and have a positive impact on the wellbeing of humans worldwide” Dr. Aube continued.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Metatron Inc (OTCMKTS:MRNJD) Announces Reverse Stock Split
Metatron Inc (OTCMKTS:MRNJD) shares surged 4,800% to $0.00490 and were flat in after-hours trading after the company announced a 1-for-78 reverse stock split. Share prices have been trading in a 52-week range of $0.00 to $0.12.
Metatron Inc is a digital content distribution and mobile application company. It is a digital content aggregator and distributor of downloadable content applications, available in internet stores. It also provides consulting services in the areas of web development, mobile software, online marketing, pay-per-click management, search engine optimization services and corporate strategy to its content generator clients and Internet-based businesses.
Aside from that, the company also provides Internet professional services which include strategic planning, web site content development, graphic design and computer programming. Its strategic services include concept creation, service selection, and campaign strategy; detailed reports and market insights; strategic direction based on market research, and strategic competition campaign analysis. It assists its clients in producing digital content and designing websites.
Metatron Inc a reverse stock split of its common stock, par value $0.00001 per share at a ratio of 1-for-78. The reverse stock split is effective immediately prior to the market opening on February 1, 2017 and the stock will be trading under the symbol of MRNJD for a period of 20 days, after which the “D” will be removed and the Company’s symbol will revert to the original symbol of “MRNJ.” This move was approved by the Company’s Board of Directors, as well as one of the company’s stockholders holding a majority of the issued and outstanding voting capital stock of the company.
In the same press release, Metatron Inc announced a strategic move by i-Mobilize into the areas of mobile encryption, and Virtual Reality for its mobile development business. With this, it will embark on re-branding Metatron mobile development business in the specific areas of mobile encryption and security, and applications for the growing market in virtual reality. The company will focus on a couple of dynamic concepts within the mobile market, and will look to reduce or shelve other projects to the back burner so as to keep our core focus on these market segments to better execute our projects to market.
A big mistake companies make these days is they spread their focus over to many projects sometimes, where it is more productive to sharpen their focus on a couple core projects within their industry, and then execute on these new concepts to market. The areas of security, or mobile encryption, and the rapid growth of virtual and augmented reality are forecasted to be the next exciting trends in the mobile application and development industry, and Metatron, Inc. plans to become a player within this area. This re-branding, or reboot of Metatron business focus, will not just be in the areas of mobile development, but also in our corporate image, and areas of how we fund the company going forward so as to keep the shareholders best interest a key focus of the Board of Directors,” said Metatron Inc CEO John Riehl.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
American Assets Capital Advisers Just Picked Up Cadiz Inc. (NASDAQ:CDZI) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Cadiz Inc. (NASDAQ:CDZI) reported that American Assets Capital Advisers has picked up 889,797 of common stock as of 2017-01-30.
The acquisition brings the aggregate amount owned by American Assets Capital Advisers to a total of 889,797 representing a 4.51% stake in the company.
For those not familiar with the company, Cadiz Inc. is a land and water resource development company with approximately 45,000 acres of land in three areas of eastern San Bernardino County, California. The Company’s primary business is to acquire and develop land with water resources for various uses, including groundwater supply, groundwater storage and agriculture. It is focused on the development of the Cadiz Valley Water Conservation, Recovery and Storage Project, which captures and conserves millions of acre-feet of native groundwater being lost to evaporation from the aquifer system beneath its approximately 34,000-acre property in the Cadiz and Fenner valleys of eastern San Bernardino County and deliver it to water providers throughout Southern California. In addition to the Cadiz/Fenner Valley property, it also owns approximately 11,000 additional acres in the eastern Mojave Desert portion of San Bernardino County, California at two separate properties. It owns over 2,000 acres near Danby Dry Lake in Ward Valley.
A glance at Cadiz Inc. (NASDAQ:CDZI)’s key stats reveals a current market capitalization of 307.15 million based on 20.75 million shares outstanding and a price at last close of $14.80 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-30, Water picked up 20,000 at a purchase price of $12.36. This brings their total holding to 2,957,660 as of the date of the filing.
On the sell side, the most recent transaction saw Brackpool unload 50,000 shares at a sale price of $12.70. This brings their total holding to 185,000 .
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Cadiz Inc. (NASDAQ:CDZI) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.